Browse drugs

…pendent predictors of CRR, but not RASi usage.Conclusion Adding RASi to standard induction therapy provided no additive benefit for …

…ed despite infection resolution. Multiple prokinetics including azithromycin, domperidone, and alimemazine were ineffective, with ongoing ga…

…ough hypersensitivity reactions and pancytopenia can occur with trientine as well, however these were not seen in our cohort.To conclude,…

…in this study (from January 2022 to January 2025), who received sorafenib treatment according to the BCLC staging system.Fifty-five patie…

…vation and limiting ECM deposition. These findings suggest that itaconate derivatives represent a promising therapeutic strategy for the …

…, patients were divided into five groups: DT, and BQTs based on minocycline (MIN-BQT), clarithromycin (CLA-BQT), furazolidone (FUR-BQT), or…

… ≥2, and inadequate response/intolerance (IR) to TNFa blockers, vedolizumab, ustekinumab, JAK inhibitors, or S1P receptor modulators (BIO/J…

…Objective Guselkumab (GUS) is a dual-acting IL-23p19 inhibitor that neutralises IL-2…

…R, PXR, VDR) with no change in expression following exposure to BA-H. Organoid viability was also unchanged following BA-H exposure.…

…n (B), ALP % change from BL (C) through 36 months of open-label seladelpar treatmentn/N = number of responders at each time point/total nu…

… and assessed their capacity to mediate pathomechanisms.Results Efgartigimod decreased all detectable AChR-specific IgG subclasses. At basel…

…r previous finding using SIK2 KO mice.Conclusion Treatment with ARN-3236, a selective SIK2 inhibitor, might produce beneficial effects i…